Evidence map›Paper›PMID 32247283›Full record

ArticlePediatric research2021

Association between faecal pH and fat absorption in children with cystic fibrosis on a controlled diet and enzyme supplements dose.

Joaquim Calvo-Lerma, Maria Roca, Mieke Boon, Carla Colombo, Barbara de Koning, Victoria Fornés-Ferrer, Etna Masip, Maria Garriga, Anna Bulfamante, Andrea Asensio-Grau and 4 more

Open access · greenAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Pediatric research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 5 countries.

Joaquim Calvo-LermaCystic Fibrosis Unit, Instituto de Investigación Sanitaria La Fe de Valencia, 46026, Valencia, Spain. joaquin_calvo@iislafe.es.ORCID http://orcid.org/0000-0001-7818-0652
Maria RocaCystic Fibrosis Unit, Instituto de Investigación Sanitaria La Fe de Valencia, 46026, Valencia, Spain.
Mieke BoonPediatric Pulmonology and Cystic Fibrosis Unit, Department of Pediatrics, University Hospitals, 3000, Leuven, Belgium.
Carla ColomboCF Center, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122, Milan, Italy.
Barbara de KoningErasmus Medical Center, Sophia Children's Hospital, Rotterdam, The Netherlands.
Victoria Fornés-FerrerTAU Analytics, Valencia, Spain.
Etna MasipCystic Fibrosis Unit, Instituto de Investigación Sanitaria La Fe de Valencia, 46026, Valencia, Spain.
Maria GarrigaHospital Universitario Ramón y Cajal, 28034, Madrid, Spain.
Anna BulfamanteCF Center, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122, Milan, Italy.
Andrea Asensio-GrauResearch Institute of Food Engineering for Development, Universitat Politècnica de València, 46022, Valencia, Spain.
Ana AndrésResearch Institute of Food Engineering for Development, Universitat Politècnica de València, 46022, Valencia, Spain.
Kris de BoeckPediatric Pulmonology and Cystic Fibrosis Unit, Department of Pediatrics, University Hospitals, 3000, Leuven, Belgium.
Jessie HulstDivision of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, ON, Canada.
Carmen Ribes-KoninckxCystic Fibrosis Unit, Instituto de Investigación Sanitaria La Fe de Valencia, 46026, Valencia, Spain.
Instituto de Investigación Sanitaria La Fe · ESKU Leuven · BEUniversitat Politècnica de València · ESUniversity of Milan · ITErasmus MC - Sophia Children’s Hospital · NLHospital for Sick Children · CAHospital Universitario Ramón y Cajal · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite treatment with pancreatic enzyme replacement therapy (PERT), patients with cystic fibrosis (CF) can still suffer from fat malabsorption. A cause could be low intestinal pH disabling PERT. The aim of this study was to assess the association between faecal pH (as intestinal pH surrogate) and coefficient of fat absorption (CFA). Additionally, faecal free fatty acids (FFAs) were quantified to determine the amount of digested, but unabsorbed fat.

methodsIn a 24-h pilot study, CF patients followed a standardised diet with fixed PERT doses, corresponding to theoretical optimal doses determined by an in vitro digestion model. Study variables were faecal pH, fat and FFA excretion, CFA and transit time. Linear mixed regression models were applied to explore associations.

resultsIn 43 patients, median (1st, 3rd quartile) faecal pH and CFA were 6.1% (5.8, 6.4) and 90% (84, 94), and they were positively associated (p < 0.001). An inverse relationship was found between faecal pH and total fat excretion (p < 0.01), as well as total FFA (p = 0.048). Higher faecal pH was associated with longer intestinal transit time (p = 0.049) and the use of proton pump inhibitors (p = 0.009).

conclusionsAlthough the clinical significance of faecal pH is not fully defined, its usefulness as a surrogate biomarker for intestinal pH should be further explored. IMPACT: Faecal pH is a physiological parameter that may be related to intestinal pH and may provide important physiopathological information on CF-related pancreatic insufficiency. Faecal pH is correlated with fat absorption, and this may explain why pancreatic enzyme replacement therapy is not effective in all patients with malabsorption related to CF. Use of proton pump inhibitors is associated to higher values of faecal pH. Faecal pH could be used as a surrogate biomarker to routinely monitor the efficacy of pancreatic enzyme replacement therapy in clinical practice. Strategies to increase intestinal pH in children with cystic fibrosis should be targeted.

Indexed as

Enzyme Replacement TherapyIntestinal AbsorptionAdolescentChildCombined Modality TherapyCystic FibrosisDietary FatsEuropeExocrine Pancreatic InsufficiencyFecesFemaleHumansHydrogen-Ion ConcentrationMalePancreasPilot ProjectsDietary Fats

Identifiers

PMID32247283
OpenAlexW3014133177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.